1. Home
  2. IMMX

IMMX

Immix Biopharma Inc.

Logo Immix Biopharma Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-12-2024 10:31am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Founded: 2014 Country:
United States
United States
Employees: N/A City: LOS ANGELES
Market Cap: 75.5M IPO Year: 2021
Target Price: $14.00 AVG Volume (30 days): 285.1K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.89 EPS Growth: N/A
52 Week Low/High: $1.40 - $7.75 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: